Report cover image

Acute Bacterial Skin and Skin Structure Infections Market, by Drug Type (Oral & Parenteral Antibiotics {Vancomycin, Linezolid, Clindamycin, Ceftaroline, Daptomycin, Dalbavancin, Tedizolid, and Others (Rifampin, Doxycycline, Minocycline, and Trimethoprim-S

Publisher Coherent Market Insights
Published Jun 20, 2022
Length 180 Pages
SKU # CMI17292100

Description

Acute Bacterial Skin and Skin Structure Infections Market, by Drug Type (Oral & Parenteral Antibiotics {Vancomycin, Linezolid, Clindamycin, Ceftaroline, Daptomycin, Dalbavancin, Tedizolid, and Others (Rifampin, Doxycycline, Minocycline, and Trimethoprim-Sulfa Methoxazol, among others)}, and Topical Antibiotics {Hydrogen Peroxide, Fusidic Acid, Mupirocin, Retapamulin, and Povidone-Iodine}), by Infection Type (Hospital Acquired ABSSSI, and Community Acquired ABSSSI), by Route of Administration (Oral, Parenteral, and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Acute bacterial skin and skin structure infections (ABSSSI) are the type of skin and soft tissue infections that affect the epidermis, dermis, and subcutaneous tissues. The U.S. Food and Drug Administration (US FDA) defines ABSSSI as lesions with cellulitis/erysipelas, wound infections, and major cutaneous abscesses occurring in a minimum surface area of 75 cm2. Pathogens such as Methicillin sensitive Staphylococcus aureus (MSSA), Methicillin resistant Staphylococcus aureus (MRSA), Beta-hemolytic Streptococcus, Escherichia coli, Enterococcus faecalis, and Pseudomonas aeruginosa are the major causes of ABSSSI. This infection is difficult to treat due to increasing prevalence of drug resistant strains, especially in Staphylococcus spp. and Enterococcus spp.

Market Dynamics

Increasing incidence of ABSSSI, rising research and development activities by market players, and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market are the major factors that are expected to drive growth of the global acute bacterial skin and skin structure infections (ABSSSI) market over the forecast period.

For instance, in July 2020, Sandoz Inc., a Switzerland based pharmaceutical company (a Novartis Division) announced the launch of Daptomycin for injection 500 mg, an AP-rated generic version of Cubicin (daptomycin) in the U.S., for treatment of adult patients with complicated skin and skin structure infections (cSSSI) (also known as ABSSSI) caused by Gram-positive bacteria and certain bloodstream infections such as right-sided infective endocarditis, and others

Key features of the study:
  • This report provides an in-depth analysis of the global acute bacterial skin and skin structure infections (ABSSSI) market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global acute bacterial skin and skin structure infections (ABSSSI) market based on the following parameters – company overview, financial performance, Material portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Arrevus, Inc., AbbVie, Inc., Aurobindo Pharma Ltd., Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., Accord Healthcare Ltd., Intas Pharmaceuticals Ltd., Fresenius SE & Co. KGaA, Sandoz Inc., Glenmark Pharmaceuticals Ltd, and Cadila Healthcare Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future Material launches, type up-gradation, market expansion, and marketing tactics
  • The global acute bacterial skin and skin structure infections (ABSSSI) market report caters to various stakeholders in this industry including investors, suppliers, material manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute bacterial skin and skin structure infections (ABSSSI) market
Detailed Segmentation:
  • Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Drug Type:
  • Oral & Parenteral Antibiotics
  • Vancomycin
  • Linezolid
  • Clindamycin
  • Ceftaroline
  • Daptomycin
  • Dalbavancin
  • Tedizolid
  • Others (Rifampin, Doxycycline, Minocycline, and Trimethoprim-Sulfa Methoxazol, among others)
  • Topical Antibiotics
  • Hydrogen Peroxide
  • Fusidic Acid
  • Mupirocin
  • Retapamulin
  • Povidone-Iodine
  • Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Infection Type:
  • Hospital Acquired ABSSSI
  • Community Acquired ABSSSI
  • Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Route of Administration:
  • Oral
  • Parenteral
  • Topical
  • Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Region:
  • North America
  • By Country
  • U.S.
  • Canada
  • Latin America
  • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • By Country/Region
  • South Africa
  • Central Africa
  • North Africa
  • Company Profiles
  • Merck & Co., Inc.*
  • Company Overview
  • Material Portfolio
  • Financial Performance
  • Key Highlights
  • Market Strategies
  • Pfizer, Inc.
  • GlaxoSmithKline plc.
  • Teva Pharmaceutical Industries Ltd.
  • Paratek Pharmaceuticals, Inc.
  • Melinta Therapeutics, Inc.
  • Arrevus, Inc.
  • AbbVie, Inc.
  • Aurobindo Pharma Ltd.
  • Amneal Pharmaceuticals LLC
  • Sun Pharmaceutical Industries Ltd.
  • Accord Healthcare Ltd.
  • Intas Pharmaceuticals Ltd.
  • Fresenius SE & Co. KGaA
  • Sandoz Inc.
  • Glenmark Pharmaceuticals Ltd
  • Cadila Healthcare Ltd.
“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

180 Pages
1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Drug Type
Market Snippet, By Infection Type
Market Snippet, By Route of Administration
Market Snippet, By Distribution Channel
Market Snippet, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
Impact Analysis
Pipeline Analysis
PEST Analysis
Regulatory Scenario
Market Trends
Key Highlights
Reimbursement Scenario
Mergers & Acquisitions
4. Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Market – Impact of Coronavirus (Covid-19) Pandemic
COVID 19 Epidemiology
Demand and Supply Chain Analysis
5. Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Market, By Drug Class, 2017 – 2030, (US$ Mn)
Introduction
Market Share Analysis, 2022 and 2030 (%)
Y-o-Y Growth Analysis, 2018 – 2030
Segment Trends
Oral & Parenteral Antibiotics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
Vancomycin
Linezolid
Clindamycin
Ceftaroline
Daptomycin
Dalbavancin
Tedizolid
Others (Rifampin, Doxycycline, Minocycline, and Trimethoprim-Sulfa Methoxazol, among others)
Topical Antibiotics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
Hydrogen Peroxide
Fusidic Acid
Mupirocin
Retapamulin
Povidone-Iodine
6. Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Market, By Infection Type, 2017 – 2030, (US$ Mn)
Introduction
Market Share Analysis, 2022 and 2030 (%)
Y-o-Y Growth Analysis, 2018 – 2030
Segment Trends
Hospital Acquired ABSSSI
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
Community Acquired ABSSSI
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
7. Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Market, By Route of Administration, 2017 – 2030, (US$ Mn)
Introduction
Market Share Analysis, 2022 and 2030 (%)
Y-o-Y Growth Analysis, 2018 – 2030
Segment Trends
Oral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
Topical
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
Parenteral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
8. Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Market, By Distribution Channel, 2017 – 2030, (US$ Mn)
Introduction
Market Share Analysis, 2022 and 2030 (%)
Y-o-Y Growth Analysis, 2018 – 2030
Segment Trends
Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
9. Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Market, By Region, 2017 – 2030, (US$ Mn)
Introduction
Market Share Analysis, By Region, 2022 and 2030 (%)
Y-o-Y Growth Analysis, For Regions, 2018–2030
North America
Market Size and Forecast, By Drug Type, 2017 – 2030, (US$ Mn)
Market Size and Forecast, By Infection Type, 2017 – 2030, (US$ Mn)
Market Size and Forecast, By Route of Administration, 2017 – 2030, (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2017 – 2030, (US$ Mn)
Market Size and Forecast, By Country, 2017 – 2030, (US$ Mn)
U.S.
Canada
Latin America
Market Size and Forecast, By Drug Type, 2017 – 2030, (US$ Mn)
Market Size and Forecast, By Infection Type, 2017 – 2030, (US$ Mn)
Market Size and Forecast, By Route of Administration, 2017 – 2030, (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2017 – 2030, (US$ Mn)
Market Size and Forecast, By Country, 2017 – 2030, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Market Size and Forecast, By Drug Type, 2017 – 2030, (US$ Mn)
Market Size and Forecast, By Infection Type, 2017 – 2030, (US$ Mn)
Market Size and Forecast, By Route of Administration, 2017 – 2030, (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2017 – 2030, (US$ Mn)
Market Size and Forecast, By Country, 2017 – 2030, (US$ Mn)
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
Market Size and Forecast, By Drug Type, 2017 – 2030, (US$ Mn)
Market Size and Forecast, By Infection Type, 2017 – 2030, (US$ Mn)
Market Size and Forecast, By Route of Administration, 2017 – 2030, (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2017 – 2030, (US$ Mn)
Market Size and Forecast, By Country, 2017 – 2030, (US$ Mn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
Market Size and Forecast, By Drug Type, 2017 – 2030, (US$ Mn)
Market Size and Forecast, By Infection Type, 2017 – 2030, (US$ Mn)
Market Size and Forecast, By Route of Administration, 2017 – 2030, (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2017 – 2030, (US$ Mn)
Market Size and Forecast, By Country, 2017 – 2030, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
Market Size and Forecast, By Drug Type, 2017 – 2030, (US$ Mn)
Market Size and Forecast, By Infection Type, 2017 – 2030, (US$ Mn)
Market Size and Forecast, By Route of Administration, 2017 – 2030, (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2017 – 2030, (US$ Mn)
Market Size and Forecast, By Country, 2017 – 2030, (US$ Mn)
South Africa
Central Africa
North Africa
10. Competitive Landscape
Heat Map Analysis
Market Share Analysis
Merck & Co., Inc.
Company Overview
Material Portfolio
Financial Overview
Key Highlights
Market Strategies
Pfizer, Inc.
Company Overview
Material Portfolio
Financial Overview
Key Highlights
Market Strategies
GlaxoSmithKline plc.
Company Overview
Material Portfolio
Financial Overview
Key Highlights
Market Strategies
Teva Pharmaceutical Industries Ltd.
Company Overview
Material Portfolio
Financial Overview
Key Highlights
Market Strategies
Paratek Pharmaceuticals, Inc.
Company Overview
Material Portfolio
Financial Overview
Key Highlights
Market Strategies
Melinta Therapeutics, Inc.
Company Overview
Material Portfolio
Financial Overview
Key Highlights
Market Strategies
Arrevus, Inc.
Company Overview
Material Portfolio
Financial Overview
Key Highlights
Market Strategies
AbbVie, Inc.
Company Overview
Material Portfolio
Financial Overview
Key Highlights
Market Strategies
Aurobindo Pharma Ltd.
Company Overview
Material Portfolio
Financial Overview
Key Highlights
Market Strategies
Amneal Pharmaceuticals LLC
Company Overview
Material Portfolio
Financial Overview
Key Highlights
Market Strategies
Sun Pharmaceutical Industries Ltd.
Company Overview
Material Portfolio
Financial Overview
Key Highlights
Market Strategies
Accord Healthcare Ltd.
Company Overview
Material Portfolio
Financial Overview
Key Highlights
Market Strategies
Intas Pharmaceuticals Ltd.
Company Overview
Material Portfolio
Financial Overview
Key Highlights
Market Strategies
Fresenius SE & Co. KGaA
Company Overview
Material Portfolio
Financial Overview
Key Highlights
Market Strategies
Sandoz Inc.
Company Overview
Material Portfolio
Financial Overview
Key Highlights
Market Strategies
Glenmark Pharmaceuticals Ltd
Company Overview
Material Portfolio
Financial Overview
Key Highlights
Market Strategies
Cadila Healthcare Ltd.
Company Overview
Material Portfolio
Financial Overview
Key Highlights
Market Strategies
Analyst Views
11. Section
References
Research Methodology
About us and Sales Contact
*Browse 49 market data tables and 35 figures on "Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market” - forecast to 2030

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us